Use of Nafamostat Mesilate for Anticoagulation in Patients With ECMO

Inclusion Criteria: 1. Age ≥ 18 years old 2. VA-ECMO or VV-ECMO was accepted after cardiac surgery. 3. The ECMO treatment team believes that systemic anticoagulation is needed 4. Sign the informed consent form Exclusion Criteria: 1. The researchers believe that there are other causes of active bleeding that are not suitable to participate in this study. 2. Long-term use of anticoagulants before establishment of ECMO 3. Antiplatelet drugs were used before the establishment of ECMO 4. Severe liver insufficiency 5. Connective tissue disease 6. There is a history of allergy to heparin or nemolastat mesylate. 7. Pregnant 8. Previous diagnosis of heparin-induced thrombocytopenia 9. Expect to die within 48 hours 10. ECPR